Medibio (ASX: MEB) (OTCQB: MDBIF) is a digital health company that has pioneered the use of objective biometrics to assist in the diagnosis and treatment of depression and other mental health disorders. Medibio's proprietary Digital Mental Health Platform uses advanced, cloud-based analytics to enable GPs and mental health clinicians to cost-effectively screen, precisely diagnose, and objectively confirm treatment effectiveness to better manage patients. Medibio’s technology also provides an objective method for the assessment of stress and mental well-being that can be translated to the non-medical workplace stress/well-being, wearable technology, and app markets.
Below is a link to the presentation currently being used in the investor road show meetings and in meetings with prospective customer partners and government entities, including multiple Departments of Veterans Affairs agencies. There is the potential for a revenue generating deal in relation to the stress and or PTSD product to be announced imminently.
